What is Deciphera?
Deciphera operates at the intersection of advanced molecular biology and clinical oncology, specializing in the discovery and development of switch-control kinase inhibitors. The company's core value proposition lies in its proprietary platform, which allows for the precise modulation of kinase activity, a critical mechanism in various oncological pathways. This technological edge has enabled the successful commercialization of QINLOCK, an FDA-approved treatment for fourth-line gastrointestinal stromal tumor (GIST), which has also secured regulatory approvals across key international markets including Australia, Canada, China, and Hong Kong.
Beyond its current commercial success, Deciphera maintains a broad portfolio of product candidates currently undergoing clinical evaluation. By leveraging deep expertise in kinase biology, the company is effectively addressing significant unmet medical needs, positioning itself as a leader in the next generation of targeted cancer therapies.
How much funding has Deciphera raised?
Deciphera has raised a total of $994.5M across 6 funding rounds:
Series B
$90M
Series C
$52M
Stock Offering
$127.5M
Stock Offering
$400M
Stock Offering
$175M
Stock Offering
$150M
Series B (2015): $90M with participation from New Leaf Venture Partners and SV Life Sciences
Series C (2017): $52M led by New Leaf Venture Partners, Sphera Global Healthcare Fund, Viking Global Investors, and Redmile Group
Stock Issuance/Offering (2017): $127.5M, investors not publicly disclosed
Stock Issuance/Offering (2019): $400M, investors not publicly disclosed
Stock Issuance/Offering (2020): $175M, investors not publicly disclosed
Stock Issuance/Offering (2022): $150M, investors not publicly disclosed
Key Investors in Deciphera
New Leaf Venture Partners
A global venture capital firm dedicated to corporate technology spinouts, providing a critical bridge between R&D labs and traditional venture capital to commercialize high-impact innovations.
Viking Global Investors
A research-intensive global investment firm that utilizes fundamental analysis to select long-term equity interests across diverse industries and geographies.
SV Life Sciences
A specialist investment firm focused on backing innovative healthcare and life science companies, providing capital and sector expertise from early growth through to value creation.
What's next for Deciphera?
With the recent $150M infusion, Deciphera is strategically positioned to accelerate its clinical pipeline and expand the global footprint of its commercial operations. The focus remains on maximizing the therapeutic potential of its switch-control kinase inhibitor platform, with an emphasis on advancing multiple candidates through rigorous clinical trials. As the company matures, the strategic deployment of this capital will likely prioritize the expansion of QINLOCK's market reach and the acceleration of R&D initiatives aimed at addressing resistant tumor types. Investors and stakeholders are closely monitoring the firm's ability to convert its robust research foundation into sustained commercial value, as it continues to refine its role as a pivotal player in the global biopharmaceutical landscape.
See full Deciphera company page
